SKYE סך נכסי הפעילות העסקית skyebioscience.com
This price chart illustrating the trading dynamics of Skye Bioscience, Inc. (SKYE) total assets, valued at 31.60, highlights the biotech's financial instability. Skye Bioscience, Inc. (SKYE) relies on the study of cannabinoids for ocular treatment while generating no sales. Meanwhile, management strictly controls expenses while advancing Nimacimab with open data. Business development is based on seeking licensing partners among industry behemoths without acquiring third-party assets.
פילוחים אנליטיים ודוחות נתונים של חברת Skye Bioscience, Inc. (SKYE)
Controlling the issuer's resource base is critical for a diversified portfolio. This metric is calculated inversely via return on assets (ROA), combining equity and debt into a single value equivalent. For Skye Bioscience, Inc. (SKYE), which has no commercial products, growth in this figure reflects only clinical development costs. The trend in balance sheet assets allows for an assessment of the company's financial stability while awaiting research results.